Leucogen plus chemo versus placebo for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 3 trial tests whether adding Leucogen to standard chemotherapy helps people with stage IV, recurrent, or metastatic nasopharyngeal cancer. It compares Leucogen versus an inactive placebo to see which better improves outcomes and manages low blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 60, and you have biopsy-proven stage IV, recurrent, or metastatic nasopharyngeal cancer
- Your cancer is not suitable for local anti-cancer treatments like surgery or radiotherapy (except limited radiation for symptom relief)
- Your general strength is good enough (Karnofsky score at least 70; sometimes can be as low as 50 if due to the tumor)
- You have at least one measurable tumor spot on scan, and it has not had local treatment like radiotherapy
- Your expected survival is at least 3 months
- Your blood and organ test results must meet minimum thresholds (for example: neutrophils, platelets, hemoglobin, kidney function, and liver tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests whether a treatment plan that includes PFLL and JS001 given first can work better than the standard combination of medicines for nasopharyngeal cancer that has spread and can’t be cured with local treatments. It aims to see how well the treatments control the cancer and how safe they are.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
This trial tests whether combining a newer chemotherapy drug (lobaplatin) with standard radiation and chemotherapy is safe and effective for adults aged 65 to 80 with a certain type of nasopharyngeal cancer that hasn't spread to distant organs.
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.